Edwards Lifesciences Corporation (EW) is expected to report fourth-quarter and full-year 2023 results soon.In the last reported quarter, the company’s adjusted earnings per share of 59 cents matched the Zacks Consensus Estimate. The company’s earnings beat estimates in three of the trailing four quarters and were in line in the other. EW has a trailing four-quarter earnings surprise of 2.03% on average.Let's see how things have shaped up before this announcement.Factors at PlaySimilar to the last reported q ...

burcu onter/iStock via Getty ImagesInvestment Thesis Edwards Lifesciences Corporation (NYSE:EW) is down 3.10% over the last year but I am bullish on the stock given its optimistic outlook for 2024 and beyond which I find very realistic and backed with strong levers. The company has a clear growth strategy, which I am confident will lead to long-term sustainable growth. Based on comparative analysis, EW appears to have higher growth rates and profitability ratios than competitors; something I believe und ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an em ...

Edwards Lifesciences Corporation (EW) is likely to grow in the coming quarters, backed by the strong prospects of the Critical Care business, one of the rapidly growing businesses of the company. The RESILIA portfolio continues to gain significant traction with widespread adoption. Within TMTT (Transcatheter Mitral and Tricuspid Therapies), new therapy introductions, clinical trial achievements and geographic expansion look promising for the company.Meanwhile, elevated expenses and foreign exchange headwind ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version access ...

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 UNITED STATES or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Edwards Lifesciences Corporation (NYSE:EW) Q3 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President, TAVR and Surgical Structural Heart Daveen Chopra - Global Leader of TMTT Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Joshua Jennings - Cowen Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Miksi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) | Title of each cla ...

Edwards Lifesciences Corporation (NYSE:EW) Q2 2023 Earnings Conference Call July 26, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President, TAVR and Surgical Structural Hear Daveen Chopra - Global Leader of TMTT Conference Call Participants Robbie Marcus - JPMorgan Matthew Taylor - Jefferies Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Josh Jennings - Cowen Chris Pasquale ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) (State or other ju ...